Equities

Proteome Sciences PLC

Proteome Sciences PLC

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (GBX)2.70
  • Today's Change0.00 / 0.00%
  • Shares traded100.31k
  • 1 Year change-55.00%
  • Beta0.1480
Data delayed at least 20 minutes, as of Nov 08 2024 13:27 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Proteome Sciences plc is a specialist provider of contract proteomics services. The Company’s services enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids. Its principal activities involve protein biomarker research and development. It uses high-sensitivity techniques to detect and characterize differentially expressed proteins in biological samples for diagnostic, prognostic and therapeutic applications. SysQuant and TMT MS2 are unbiased methods for identifying and contextualizing new targets and defining mechanisms of biological activity, while analysis using Super-Depletion and TMTcalibrator provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. In addition, it has invented and developed the technology for TMT and TMTpro, and manufactures these small, protein-reactive chemical reagents for multiplex quantitative proteomics.

  • Revenue in GBP (TTM)4.04m
  • Net income in GBP-4.08m
  • Incorporated1993
  • Employees35.00
  • Location
    Proteome Sciences PLCCoveham House, Downside Bridge RoadADDLESTONE KT11 3EPUnited KingdomGBR
  • Phone+44 207 043 2116
  • Fax+44 203 637 7516
  • Websitehttps://www.proteomics.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Deltex Medical Group plc1.78m-1.29m1.71m37.00--0.5862--0.9581-0.0007-0.00070.0010.00150.31560.91135.2348,135.14-22.92-14.66-35.89-21.8162.2171.84-72.60-32.930.4855-3.310.4245---28.44-18.55-11.97--9.78--
Feedback plc1.18m-3.30m2.60m24.00--0.3401--2.20-0.2474-0.24740.08860.57330.1178--7.70---32.88-28.12-35.63-30.7293.3091.80-279.16-312.58--------15.2715.98-13.03--26.72--
Image Scan Holdings Plc2.56m-11.06k3.90m14.00--2.8042.321.52-0.00008-0.000080.01870.01021.072.385.38183,209.30-0.4626-1.15-0.7257-1.7750.5751.36-0.4312-1.011.69--0.00--47.98-3.08145.65--40.19--
Surgical Innovations Group Plc12.54m-622.00k5.13m101.00--0.513263.340.4092-0.0007-0.00070.01340.01070.85252.605.48124,148.50-4.23-8.19-5.38-9.9428.8532.51-4.96-13.310.8677-3.510.1225--5.941.84-292.80--7.20--
Aptamer Group PLC860.00k-2.96m5.28m38.00--1.45--6.14-0.0075-0.00750.00210.00190.31153.783.0322,631.58-107.14---227.63--29.07---343.95--1.17-54.110.4795---50.91--62.25------
Myhealthchecked PLC9.39m-1.04m6.50m10.00--0.8627--0.692-0.0201-0.02010.1810.14491.035.1726.92939,400.00-11.41-7.24-12.91-10.397.9222.82-11.06-5.1311.58--0.0016---50.81368.95-110.48---2.00--
Rua Life Sciences PLC2.19m-1.44m6.67m33.00--0.9289--3.04-0.0551-0.05510.06530.11570.31684.303.9166,393.94-20.82-24.63-22.39-26.8181.06---65.72-97.078.81-23.340.0514--0.550736.4628.11--122.88--
Genincode PLC2.60m-5.94m7.34m36.00--2.61--2.83-0.0507-0.05070.01930.01590.441116.953.4872,194.45-100.88---127.83--49.44---228.70--2.55--0.0849--51.05---26.21------
Cambridge Nutritional Sciences PLC9.77m-328.00k7.61m94.00--0.786523.650.779-0.0015-0.00150.04110.04070.69085.394.62103,978.70-2.32-11.43-2.60-12.9861.8658.79-3.36-26.725.03--0.0151--29.532.2289.66---53.43--
Proteome Sciences plc4.04m-4.08m7.97m35.00------1.98-0.0138-0.01380.0137-0.01780.39274.694.61115,285.70-39.69-1.22----2.1154.53-101.07-2.200.1388-3.701.63---35.3710.52-284.38--126.22--
Verici DX PLC3.35m-3.72m8.23m19.00--1.08--2.45-0.0204-0.02040.01710.03150.4038--5.71239,531.30-44.82---58.12--77.06---110.99------0.0183------23.43------
Data as of Nov 08 2024. Currency figures normalised to Proteome Sciences PLC's reporting currency: UK Pound GBX

Institutional shareholders

34.68%Per cent of shares held by top holders
HolderShares% Held
Vulpes Investment Management Pte Ltd.as of 13 Apr 202367.79m22.97%
Hargreaves Lansdown Asset Management Ltd.as of 03 Sep 202414.63m4.96%
Jarvis Investment Management Ltd.as of 03 Sep 20248.75m2.97%
James Brearley & Sons Ltd.as of 03 Sep 20243.33m1.13%
Rowan Dartington & Co. Ltd. (Broker)as of 03 Sep 20242.36m0.80%
Walker Crips Investment Management Ltd.as of 03 Sep 20241.88m0.64%
IG Markets Ltd.as of 03 Sep 20241.35m0.46%
Winterflood Securities Ltd (Market-Maker)as of 03 Sep 2024898.00k0.30%
J. M. Finn & Co. Ltd.as of 03 Sep 2024728.00k0.25%
HSBC Global Asset Management (UK) Ltd.as of 03 Sep 2024643.00k0.22%
More ▼
Data from 11 Apr 2024 - 09 Oct 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.